Form D · Biotechnology
Remedium Bio Inc.
Needham, MA · CIK 0001892414
Offering snapshot reported May 18, 2026 · SEC filing
- Reported sold
- $1.5M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 6, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 18, 2026 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Aug 28, 2024 | Amendment | $4,434,955 | $3,064,955vs Nov 9, 2021 | 26 | SEC filing |
| Nov 9, 2021 | Initial | $1,370,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-584420
Source: Form D, filed May 18, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luppino Francesco | Director, Executive |
| Alexei Goraltchouk | Director, Executive |
| Richard Hague | Director |
| Frank Luppino | Director, Executive |
| Harry Robb | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1116 Great Plain Avenue
Needham, MA, 02492
Needham, MA, 02492